Aktis Oncology, Inc.

AKTS Nasdaq SEC CIK 2035832
Follow Aktis Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3.9M +147.3% vs same quarter last year
Net income −$29.9M −92.7% vs same quarter last year
EPS, diluted −$0.54 +97.2% vs same quarter last year
Operating cash flow −$26.1M −71.1% vs same quarter last year
Revenue by quarter
$1.4M
$1.6M
$1.6M
$3.2M
$3.4M
$3.9M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing